Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2021 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2020
Slide 1: Q1 FY2021 Earnings Presentation
Q1 FY2021 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Highlights
Highlights Management Perspective Q1 FY2021 vs. Q1 FY2020 “Lincoln Pharma delivered a robust performance despite a o Total Income of Rs. 1,056 million, up 7.6% challenging economic and business environment globally due to COVID-19. Export business has shown remarkable growth o EBITDA of Rs. 240 mill
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q1 y-o-y Q4 q-o-q Particulars (mn.) FY2021 FY2020 Growth (%) FY2020 Growth (%) Net Revenue 1,056 981 7.6% 827 27.8% EBITDA 240 203 17.8% 128 87.2% Margin (%) 22.7% 20.7% 15.5% PBT 214 178 20.0% 115 85.7% Margin (%) 20.3% 18.2% 14.0% Profit Afte
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 24.6% 24.5% Respiratory Systems 23.1% 25.7% Therapeutic Area 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones 0.6% 0.1% Q1 FY21 13% Q1 FY20 15% Musculo-Skeletal System 4.4% 4.4% 14% Parasitology
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) EBITDA (Rs. million) and Margin (%) 23.6% 22.7% 20.7% 19.7% 7.6% 5.4% 7.6% 16.0% 15.5% (3.9)% 981 1,152 1,016 827 1,056 203 272 162 128 240 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 PBT (Rs. milli
Slide 6: Performance Trend
Performance Trend Total Debt / LTM EBITDA Total Debt / Net Worth 0.54x 0.54x 0.15x 0.12x 0.25x 0.18x 0.06x 0.04x 0.07x 0.02x Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 ROCE1 RONW2 21.1% 21.8% 21.3% 16.8% 16.5% 17.0% 16.4% 16.5% 19.8% 19.3% Q1 FY20 Q2 FY20 Q3 FY20
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Jun-20 Mar-20 Jun-19 Credit Rating Long Term Debt 7.5 8.4 10.5 o CRISIL Short Term Debt 135.4 42.3 384.3 ▪ Long term rating: A-/Stable Total Debt 142.9 50.7 394.8 ▪ Short term rating: A2+ Less: Cash & Cash o ICRA 163.0 122.3 135.9 Equivalents ▪ Long term rating: A-/Sta
Slide 8: Recent Developments
Recent Developments Secured a patent for Diclofenac Rectal Spray International operations • Recently the company has been awarded with a patent for its liquid Diclofenac Metered- • Aggressively started the business in Francophone African countries and some of the Dose Rectal Spray (Diclofenac Rectal
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.6% 3.2% 2.4% 2.0% 2.7% 148.1 135.1 Senior Scientist 15 117.3 Junior Scientist 18 1.6% 88.5 Analysts 18 79.5 72.6 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 7 Patents granted 1,700 Registered products 60+ 26 25 Patents applications 700 in pipeline Countries States across India 600+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 11: Key Milestones
Key Milestones 1 MW Solar roof top plant Received WHO – Becomes Public Launch 3 products which are installed Covered 80% Developed & GMP for plant / Limited Company Installed Windmill first time in India. Entered in of all India launched 2 more production unit from a Partnership 600 KVA more (regula
Slide 12: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Asia : Afghanistan, Armenia, America : Bolivia, Africa: Angola, Benin, Botswana, Azerbaijan, Bhutan, Cambodia, Chile, Costa Rica, Bu
Slide 13: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Eye Preparation Products Range Anti-asthmatics Drops/Ointment Vitamins / Anti-bacterial / Analgesic / Anti- Anti-malarial Minerals / Anti- Anti-viral/ Anti- Otology p
Slide 15: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 α-β Arteether Injection Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride 150mg/ 2 ml Effective Anti- Malarial Kingping Heparin
Slide 16: Key Developments
Key Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient com
Slide 17: Key Developments
Key Developments o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Exten
Slide 18: Key Developments
Key Developments o USP INFITY - YS • Most stable derivative of Vitamin C (at 450C) • Easy to penetrate skin • Molecular weight of Hyaluronic acid in INFITY – YS is equivalent to 1000 KDal o USP INFITY - HS • Revitalized the DPC • Covering all aspects of Baldness in one solution • Powered with the Ha
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060. Gujarat, INDIA. Phone: +91-79-41078000 • Fax: +91-79-41078062 E-mail: info@lincolnpharma.com • Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 KP Sompura Ajay Tambhale / Bopiah Ganapathy Finance H
Lincoln Pharmaceuticals — Q1 FY2021 Earnings Presentation on 6ix